[
    "{\"step_by_step_thinking\": \"To determine the most recent oral direct thrombin inhibitor (DTI) for acute stroke prevention, we need to review the options and identify the drug that was approved most recently. \\n\\nA. Ximelagatran: Ximelagatran was a DTI that was approved by the FDA in 2004. It was later withdrawn from the market due to safety concerns. Therefore, it is not the most recent option. \\n\\nB. Idraparinux: Idraparinux is not a DTI. It is a long-acting anticoagulant that inhibits factor Xa. Therefore, it is not the most recent option. \\n\\nC. Dabigatran: Dabigatran is an oral DTI that was approved by the FDA in 2010 for the prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation. It is currently used for acute stroke prevention and is the most recent option among the choices given. \\n\\nD. Wasfarean: Wasfarean is not a known medication and is not a DTI. Therefore, it is not the most recent option. \\n\\nBased on this analysis, the most recent oral DTI for acute stroke prevention is Dabigatran.\", \"answer_choice\": \"C. Dabigatran\"}"
]